NCT01349335已完成2 期
A Phase 2 Randomized, Double-blinded, Multicenter and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Different Doses of Tolvaptan Tablet in Patients With Cirrhotic Ascites
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- Body weight changes after 7 days of treatment (quantity of changes)
研究概览
简要总结
To observe the safety/efficacy of tolvaptan for treatment of patients with hepatic cirrhosis with ascites and exploring the dosage-effect relations of the drug.
详细描述
Tolvaptan is able to exert hydragogue diuretic effects (water diuresis) via inhibition of water reabsorption by renal collecting ducts without corresponding increase in electrolyte excretion. It has been confirmed that tolvaptan is able to increase urine volume without any adverse effects on renal functions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hepatic cirrhosis patients after 7days treatment of loop diuretics and aldosterone antagonist but still with ascites
- •Hospitalized patients or those who can be hospitalized in this trial between observation period and posttherapeutic observation (Visits at clinic will be allowed after day 8);
- •During the observation period (-3 day to -1 day ), subjects whose body weight difference fall within ±1.0 kg range 2 days (day-2 and day -1) prior to initiation of trial drug treatment;
- •Ages: ≥18 and ≤75 years of age;
- •Genders: men or women;
- •Signed the Informed Consent Form.
排除标准
- •Patients with the following diseases, complications or symptoms:
- •Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher);
- •Malignant ascites;
- •Uncontrolled spontaneous bacterial peritonitis;
- •Patients are likely to experience alimentary tract hemorrhage during the trial;
- •Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4);
- •Anuria (daily urine volume below 100mL);
- •Dysuria resulting from urethral stricture, calculus and tumors.
- •Patients with the following medical history:
- •Alimentary tract hemorrhage within 10 days prior to screening;
- •Cerebrovascular accident within 1 month prior to screening;
- •Gout attack within 1 month prior to screening;
- •Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride)
- •Systolic pressure below 90mmHg at screening;
- •Patients with the following abnormalities in laboratory examinations at screening:
- •Serum creatinine exceeds 2.5X upper limits of normal, serum Na+>145mmol/L (or exceeds upper limits of normal), serum K+>5.5mmol/L, uric acid>8.0mg/dL (476μmol/L), Child-pugh scale greater than
- •Patients cannot take drugs orally;
- •Pregnant or breast-feeding patients or women at child-bearing ages without taking acceptable contraceptive measures;
- •Patients received albumin or other blood preparations within 4 days prior to trial drug administration;
- •Patients participated in clinical trials of other drugs within 1 month prior to screening;
- •Patients participated in tolvaptan trials and took tolvaptan previously;
- •Patients are unsuitable to participate in this trial in investigators' opinion.
研究组 & 干预措施
1. tolvaptan
Experimental
15 mg, P.O., Qd, for 7 days,
干预措施: Tolvaptan (Drug)
2 tolvaptan
Experimental
30 mg, P.O., Qd, for 7 days,
干预措施: Tolvaptan (Drug)
3. Placebo
Experimental
30mg,P.O.,Qd, for 7 days.
干预措施: placebo (Drug)
结局指标
主要结局
Body weight changes after 7 days of treatment (quantity of changes)
时间窗: from day1 to day7
次要结局
- Body weight change after 4 days of treatment (quantity of changes)(from day1 to day4)
- Waist circumference after 4 and 7 days of treatment (quantity and rate of changes)(from day1 to day7)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis AscitesAscitesHepatic CirrhosisNCT01349348Otsuka Beijing Research Institute535
已完成
2 期
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic PatientsLiver CirrhosisNCT00592475Cumberland Pharmaceuticals20
已完成
2 期
Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLFAcute-On-Chronic Liver FailureNCT02946554Cellaion SA24
已完成
不适用
Efficacy and Safety of Tolvaptan in Cirrhotic Patients With HyponatremiaHyponatremiaLiver CirrhosisNCT01850940Beijing Friendship Hospital98
招募中
2 期
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesCirrhosis, LiverCirrhosis EarlyCirrhosis Due to Hepatitis BCirrhosis AdvancedCirrhosis InfectiousCirrhosis AlcoholicCirrhosis Due to Hepatitis CCirrhosisNCT05832229National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256